We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$956M
AUM Growth
+$110M
Cap. Flow
+$88M
Cap. Flow %
9.21%
Top 10 Hldgs %
34.18%
Holding
136
New
4
Increased
63
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$10.5M
2
ALGN icon
Align Technology
ALGN
+$9.68M
3
CELG
Celgene Corp
CELG
+$9.59M
4
ELV icon
Elevance Health
ELV
+$9.1M
5
COR icon
Cencora
COR
+$7.21M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$7.35M
2
CI icon
Cigna
CI
+$4.96M
3
BCR
CR Bard Inc.
BCR
+$4.65M
4
CNC icon
Centene
CNC
+$4.38M
5
ALKS icon
Alkermes
ALKS
+$4.36M

Sector Composition

Rank Sector Weight
1 Healthcare 94.19%
2 Financials 0.94%
3 Industrials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
101
Cardinal Health
CAH
$53.5B
$1.34M 0.14%
20,000
– –
BIVV
102
DELISTED
Bioverativ Inc. Common Stock
BIVV
$1.3M 0.14%
22,750
– –
DVAX
103
DELISTED
Dynavax Technologies
DVAX
$1.28M 0.13%
+59,500
New +$941K
XENT
104
DELISTED
Intersect ENT, Inc
XENT
$1.28M 0.13%
41,000
-59,000
-59% -$1.75M
EXEL icon
105
Exelixis
EXEL
$14.1B
$1.26M 0.13%
52,000
– –
HMSY
106
DELISTED
HMS Holdings Corp.
HMSY
$1.06M 0.11%
53,500
+3,500
+7% +$65.1K
PFE icon
107
Pfizer
PFE
$143B
$1.04M 0.11%
30,777
– –
PODD icon
108
Insulet
PODD
$11.4B
$991K 0.1%
18,000
+1,000
+6% +$54.6K
GKOS icon
109
Glaukos
GKOS
$9.21B
$990K 0.1%
30,000
+7,500
+33% +$285K
ENDP
110
DELISTED
Endo International plc
ENDP
$985K 0.1%
115,000
– –
NVRO
111
DELISTED
NEVRO CORP.
NVRO
$972K 0.1%
10,700
+1,000
+10% +$85.6K
INO icon
112
Inovio Pharmaceuticals
INO
$92.1M
$913K 0.1%
12,000
– –
COTV
113
DELISTED
Cotiviti Holdings, Inc.
COTV
$781K 0.08%
21,708
+708
+3% +$26.7K
MDCO
114
DELISTED
Medicines Co
MDCO
$722K 0.08%
19,500
– –
CVS icon
115
CVS Health
CVS
$137B
$716K 0.07%
8,800
-24,600
-74% -$1.95M
VAR
116
DELISTED
Varian Medical Systems, Inc.
VAR
$700K 0.07%
7,000
– –
ITCI
117
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$631K 0.07%
40,000
– –
GWPH
118
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$609K 0.06%
6,000
– –
EVHC
119
DELISTED
Envision Healthcare Holdings Inc
EVHC
$586K 0.06%
13,026
– –
QTNT
120
DELISTED
Quotient Limited Ordinary Shares
QTNT
$542K 0.06%
2,750
– –
CEMP
121
DELISTED
Cempra, Inc.
CEMP
$536K 0.06%
165,000
– –
ADMS
122
DELISTED
Adamas Pharmaceuticals
ADMS
$508K 0.05%
+24,000
New +$440K
TBPH icon
123
Theravance Biopharma
TBPH
$877M
$494K 0.05%
14,428
– –
ICPT
124
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$493K 0.05%
8,500
– –
MYGN icon
125
Myriad Genetics
MYGN
$584M
$470K 0.05%
13,000
– –
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2017 Portfolio in Review

As of Q3 2017, Bellevue Group held 136 positions worth $956M, up 13% from $846M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Bellevue Group deployed $88M of net new capital in Q3 2017, opening 4 new positions and adding to 63 existing holdings. Its largest new stake was Henry Schein: 48,450 shares worth $3.12M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $7.35M trimmed.

  • Bellevue Group's largest Q3 2017 buy was Henry Schein: 48,450 shares worth $3.12M.
  • Bellevue Group added most to Illumina in Q3 2017, an estimated $10.5M increase.
  • Bellevue Group's biggest Q3 2017 reduction was Medtronic, cutting an estimated $7.35M.
  • Bellevue Group fully exited China Biologic Products Holdings, Inc. in Q3 2017, selling an estimated $4.1M.
  • Bellevue Group's ten largest holdings make up 34% of its $956M portfolio in Q3 2017.
  • Bellevue Group opened 4 new positions and closed 5 in Q3 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $956M.

Based on Bellevue Group's 13F filing for Q3 2017, filed 13 Nov 2017.